A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.
A new clinical trial is investigating whether removing clots using a modified access point can better prevent post-thrombotic syndrome in patients with extensive deep vein thrombosis.
May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.
A large population study found that individuals with Down syndrome face a significantly higher risk of stroke, particularly at younger ages, while their risk of heart attack is generally similar to the general population but elevated before age 40.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Short sleep, late blood draws, and intense workouts significantly change common cardiovascular biomarkers, suggesting key variables often go unaccounted for in heart risk assessments.
The FDA has approved Abbott’s Tendyne system, the first transcatheter mitral valve replacement for patients with severe mitral annular calcification who are ineligible for open-heart surgery.